| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/09540260600583114 |
| P698 | PubMed publication ID | 16777667 |
| P2093 | author name string | John Waddington | |
| Krishna Vaddadi | |||
| Jerry Clifford | |||
| Kerstin Hakansson | |||
| P2860 | cites work | Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats | Q48960746 |
| Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies | Q28247669 | ||
| The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment | Q28256285 | ||
| The effects of clozapine on tardive dyskinesia | Q28322745 | ||
| Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats | Q28332347 | ||
| Antipsychotic drugs differentially modulate apolipoprotein D in rat brain | Q28568529 | ||
| The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis | Q30047193 | ||
| Possible association between tardive dyskinesia and altered carbohydrate metabolism. | Q51639165 | ||
| The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. | Q51944305 | ||
| Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. | Q51946852 | ||
| Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. | Q51952242 | ||
| Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. | Q52033994 | ||
| Tardive dyskinesia in psychiatric patients with substance use disorders. | Q52061337 | ||
| Orofacial dyskinesia and the alcohol dependence syndrome | Q52078518 | ||
| Tardive dyskinesia. A discontinuation study. | Q52092107 | ||
| A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. | Q52117074 | ||
| CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. | Q52976757 | ||
| Sustained Remission of Positive and Negative Symptoms of Schizophrenia Following Treatment With Eicosapentaenoic Acid | Q60491837 | ||
| Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients | Q61713951 | ||
| Increased tardive dyskinesia in alcohol-abusing schizophrenic patients | Q67514455 | ||
| Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses | Q68148411 | ||
| Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy | Q68983997 | ||
| An experimental model of tardive dyskinesia | Q69454785 | ||
| Parkinson's disease and dementia | Q69855984 | ||
| Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia | Q69899091 | ||
| Essential fatty acid supplementation in tardive dyskinesia | Q70141608 | ||
| The desaturation step in the animal biosynthesis of polyunsaturated fatty acids | Q70534756 | ||
| Positive and negative subtypes in acute schizophrenia | Q70585034 | ||
| Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists | Q71293074 | ||
| Schizophrenia, tardive dyskinesia and essential fatty acids | Q71581817 | ||
| Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933 | Q71719471 | ||
| Schizophrenic symptoms and dietary intake of n-3 fatty acids | Q71803016 | ||
| Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis | Q72496545 | ||
| Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs | Q72548866 | ||
| Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients | Q72565505 | ||
| Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia | Q72918910 | ||
| Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics | Q73107331 | ||
| Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia | Q73307497 | ||
| Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia | Q73960227 | ||
| Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms | Q81632280 | ||
| Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. | Q31005816 | ||
| Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats | Q31545322 | ||
| Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis | Q32068772 | ||
| Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia | Q33179595 | ||
| Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? | Q33881866 | ||
| Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study | Q33923683 | ||
| The endocannabinoid system as a target for therapeutic drugs. | Q33934278 | ||
| Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets | Q33946795 | ||
| Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder | Q33964656 | ||
| Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment | Q33973980 | ||
| Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia | Q34059501 | ||
| Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease | Q34120728 | ||
| Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. | Q34303593 | ||
| Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice | Q34331157 | ||
| Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa? | Q34376428 | ||
| Pharmacology of cannabinoid CB1 and CB2 receptors. | Q34442847 | ||
| Ageing and the free radical theory | Q34445896 | ||
| Reactive oxygen species and protein oxidation in aging: a look back, a look ahead | Q34497908 | ||
| Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia | Q34515196 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. | Q34673177 | ||
| Oxidative mechanisms and tardive dyskinesia | Q35017644 | ||
| Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications | Q35102465 | ||
| Essential fatty acids in Huntington's disease | Q35913578 | ||
| Metabolic risk during antipsychotic treatment | Q36095376 | ||
| Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders | Q36187714 | ||
| Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia | Q36346334 | ||
| Prostaglandin E1 in normal human skin: methodological evaluation, topographical distribution and data related to sex and age. | Q36633258 | ||
| Oxygen radicals and neuropsychiatric illness. Some speculations | Q37152812 | ||
| Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum | Q38323715 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. | Q38375674 | ||
| The importance of free radicals and catalytic metal ions in human diseases | Q39837663 | ||
| Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. | Q40393306 | ||
| Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia | Q40577513 | ||
| The membrane hypothesis of schizophrenia | Q40582385 | ||
| Oxidative stress, glutamate, and neurodegenerative disorders | Q40618533 | ||
| N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients | Q40835150 | ||
| Oxidative injury and potential use of antioxidants in schizophrenia | Q41185173 | ||
| Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation | Q41185182 | ||
| The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent | Q41741791 | ||
| Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia | Q42172026 | ||
| Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition | Q42280555 | ||
| Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarboxylase messenger RNA in the reticular thalamic nucleus | Q42435339 | ||
| Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. | Q42517324 | ||
| Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats | Q42536101 | ||
| Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group | Q43546708 | ||
| Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor | Q43722712 | ||
| Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study | Q43790293 | ||
| MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment | Q43940983 | ||
| Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia | Q44259395 | ||
| omega-3 Fatty acid for schizophrenia | Q44265311 | ||
| Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia | Q44288274 | ||
| Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. | Q44292648 | ||
| n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice | Q44524041 | ||
| Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum | Q44541929 | ||
| Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia | Q44576785 | ||
| Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia | Q44602602 | ||
| Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients | Q44876103 | ||
| Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia | Q44902098 | ||
| Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. | Q44956219 | ||
| Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia | Q44984756 | ||
| Haloperidol- and clozapine-induced oxidative stress in the rat brain | Q45011874 | ||
| Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. | Q45160995 | ||
| Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia | Q45177150 | ||
| Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. | Q45223107 | ||
| Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims | Q45287377 | ||
| Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. | Q45289172 | ||
| Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. | Q45290294 | ||
| Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial | Q45297817 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease | Q45305057 | ||
| A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids | Q45305704 | ||
| Association of diabetes with dyskinesia in older psychosis patients. | Q45959743 | ||
| Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study. | Q45981567 | ||
| Rate of tardive dyskinesia in hospitalized patients. | Q45991351 | ||
| Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats | Q46195824 | ||
| Oxidative stress during treatment with first- and second-generation antipsychotics | Q46531475 | ||
| Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center | Q46589708 | ||
| II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. | Q46644929 | ||
| Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness | Q46701452 | ||
| A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases | Q48149829 | ||
| Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms | Q48160036 | ||
| Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms | Q48284642 | ||
| Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia | Q48396958 | ||
| Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum | Q48400646 | ||
| The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia | Q48468665 | ||
| Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine | Q48636438 | ||
| Fatty acid levels in the brains of schizophrenics and normal controls | Q48639133 | ||
| P433 | issue | 2 | |
| P921 | main subject | dyskinesia | Q629444 |
| fatty acid | Q61476 | ||
| P304 | page(s) | 133-143 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | International Review of Psychiatry | Q15752216 |
| P1476 | title | Tardive dyskinesia and essential fatty acids | |
| P478 | volume | 18 |
| Q38657158 | Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. |
| Q38545655 | Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials |
| Q37868985 | Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. |
| Q24599912 | New and emerging treatments for symptomatic tardive dyskinesia |
| Q38306593 | Tardive dyskinesia (syndrome): Current concept and modern approaches to its management |
Search more.